SUMO2: A Potential Drug Target and Biomarker for Multiple Sclerosis

Target Name: SUMO2

NCBI ID: G6613

SUMO2

SUMO2: A Potential Drug Target and Biomarker for Multiple Sclerosis

Multiple sclerosis (MS) is a chronic autoimmune disorder that affects the central nervous system, leading to a range of symptoms such as muscle weakness, vision problems, and fatigue. Currently, there is no cure for MS, and numerous treatments are available to manage the symptoms. SUMO2, a small ubiquitin-related modifier 2, has been identified as a potential drug target and biomarker for MS. In this article, we will explore the biology of SUMO2 and its potential as a drug target for MS.

The biology of SUMO2

SUMO2 is a protein that plays a critical role in the regulation of protein-protein interactions and ubiquitination, processes that are central to the immune system. SUMO2 is a small molecule that can interact with other proteins to modulate their activity and localization. SUMO2 has been shown to play a role in the regulation of immune cell function, and it has been implicated in the development and progression of MS.

SUMO2 has been shown to regulate the activity of multiple immune cell types, including T cells, B cells, and dendritic cells. SUMO2 has been shown to interact with the cytokine TGF-β and to regulate the activity of the transcription factor NF-kappa-B. These interactions between SUMO2 and immune cells are important for the regulation of immune cell function and may be involved in the development of MS.

SUMO2 has also been shown to play a role in the regulation of the immune response to infections, including HIV. SUMO2 has been shown to interact with the proteinStat3, which is a critical regulator of the immune response to HIV infection. These interactions between SUMO2 and Stat3 are important for the regulation of HIV replication and may be important for the development of HIV-related MS.

Potential drug targets for SUMO2

SUMO2 has been shown to have a number of potential drug targets, including those related to inflammation, immune cell function, and the regulation of protein-protein interactions. One potential drug target for SUMO2 is the protein heat shock protein HSP70, which is known to interact with SUMO2 and to play a role in the regulation of protein-protein interactions.

SUMO2 has also been shown to interact with the protein SIRT1, which is a natural antioxidant that is involved in the regulation of cellular stress. SUMO2 has been shown to interact with SIRT1 and to regulate its activity, which may be important for the regulation of cellular stress and the development of MS.

Another potential drug target for SUMO2 is the protein T-cell factor (TCF), which is involved in the regulation of T cell development and function. SUMO2 has been shown to interact with TCF and to regulate its activity, which may be important for the regulation of T cell function and the development of MS.

SUMO2 has also been shown to interact with the protein PDGF-尾, which is involved in the regulation of cellular growth and differentiation. SUMO2 has been shown to interact with PDGF-尾 and to regulate its activity, which may be important for the regulation of cellular growth and differentiation and the development of MS.

Biomarkers for SUMO2

SUMO2 has been shown to play a role in the regulation of multiple immune cell functions, including T cell function, B cell function, and the regulation of the immune response to infections. Therefore, SUMO2 may be a useful biomarker for the diagnosis and assessment of MS.

SUMO2 has been shown to

Protein Name: Small Ubiquitin Like Modifier 2

Functions: Ubiquitin-like protein that can be covalently attached to proteins as a monomer or as a lysine-linked polymer. Covalent attachment via an isopeptide bond to its substrates requires prior activation by the E1 complex SAE1-SAE2 and linkage to the E2 enzyme UBE2I, and can be promoted by an E3 ligase such as PIAS1-4, RANBP2, CBX4 or ZNF451 (PubMed:26524494). This post-translational modification on lysine residues of proteins plays a crucial role in a number of cellular processes such as nuclear transport, DNA replication and repair, mitosis and signal transduction. Polymeric SUMO2 chains are also susceptible to polyubiquitination which functions as a signal for proteasomal degradation of modified proteins (PubMed:18408734, PubMed:18538659, PubMed:21965678, PubMed:9556629). Plays a role in the regulation of sumoylation status of SETX (PubMed:24105744)

The "SUMO2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SUMO2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets